A randomized,blinded,parallel-group,pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis
Free accessOtherFirst published online January, 2010
A randomized,blinded,parallel-group,pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis
Background: Mycophenolate mofetil (MMF, CellCept®) has been utilized as an antirejection agent in transplant recipients and in patients with myriad autoimmune disorders including multiple sclerosis (MS).
Objective: To investigate radiographic and clinical safety involving monotherapy use of daily oral MMF (1 g b.i.d.) versus weekly intramuscular interferon beta 1a (Avonex ® at 30 mcg) in relapsing-remitting MS (RRMS).
Methods: We organized a randomized, serial, 6-monthly, MRI-blinded, parallel-group multicenter pilot study to determine the safety of MMF versus interferon beta monotherapy in 35 untreated patients with RRMS, all of whom exhibited evidence of gadolinium (Gd) enhancement on a screening MRI of the brain. The primary outcome was the reduction in the cumulative mean number of combined active lesions (CAL), new Gd-enhancing lesions, and new T2 lesions on MRI analyses.
Results: Both interferon beta and MMF appeared safe and well tolerated in the majority of patients. There was no difference between MMF therapy and the standard regimen of interferon beta therapy on the primary safety MRI endpoints of the study. However, the MMF group showed a trend toward a lower accumulation of combined active lesions, CAL, Gd and T2 lesions when compared with interferon beta treated patients.
Conclusions: The results from this pilot study suggest that the application of MMF monotherapy in MS deserves further exploration.
Ahrens, N., Salama, A. and Haas, J. ( 2001) Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol248: 713-714.
2.
Allison, A.C. and Eugui, E.M. ( 1993) The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol14: 353-380.
3.
Allison, A.C., Kowalski, W.J., Muller, C.D. and Eugui, E.M. ( 1993) Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci696: 63-87.
4.
Ameen, M., Smith, H.R. and Barker, J.N. ( 2001) Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol26: 480-483.
5.
Bar-Zohar, D., Agosta, F., Goldstaub, D. and Filippi, M. ( 2008) Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. Mult Scler14: 719-727.
6.
Barkhof, F. and Filippi, M.(2009) MRI - the perfect surrogate marker for multiple sclerosis? Nat Rev Neurol5: 182-183.
7.
Barten, M.J., van Gelder, T., Gummert, J.F., Boeke, K., Shorthouse, R., Billingham, M.E. et al. (2002a) Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant2: 719-732.
8.
Barten, M.J., van Gelder, T., Gummert, J.F., Shorthouse, R. and Morris, R.E. ( 2002b) Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo. Transpl Immunol10: 1-14.
9.
Berger, J.R. and Houff, S.(2009) Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol65: 367-377.
10.
Blaheta, R.A., Leckel, K., Wittig, B., Zenker, D., Oppermann, E., Harder, S. et al. (1999) Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc31: 1250-1252.
11.
Chaudhry, V., Cornblath, D.R., Griffin, J.W., O’Brien, R. and Drachman, D.B. ( 2001) Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology56: 94-96.
12.
Ciafaloni, E., Massey, J.M., Tucker-Lipscomb, B. and Sanders, D.B. ( 2001) Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology56: 97-99.
13.
Cohen, J.A. ( 2009) Emerging therapies for relapsing multiple sclerosis . Arch Neurol66: 821-828.
14.
Corboy, J.R., Goodin, D.S. and Frohman, E.M. ( 2003) Disease-modifying therapies for multiple sclerosis . Curr Treat Options Neurol5: 35-54.
15.
Daina, E., Schieppati, A. and Remuzzi, G. ( 1999) Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med130: 422-426.
16.
Ellis, R. and Boggild, M.(2009) Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?Mult Scler15: 505-508.
17.
Filippi, M. and Rocca, M.A. ( 2009) Functional MR imaging in multiple sclerosis. Neuroimaging Clin N Am19: 59-70.
18.
Food and Drug Administration (2009) Drug Safety Information for Health Care Professionals [online]. Available at: http://fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm072438.htm.
19.
Frohman, E.M., Brannon, K., Racke, M.K. and Hawker, K. ( 2004) Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol27: 80-83.
20.
Frohman, E.M., Racke, M.K. and Raine, C.S. ( 2006) Multiple sclerosis - the plaque and its pathogenesis . N Engl J Med354: 942-955.
21.
Gelber, A.C., Nousari, H.C. and Wigley, F.M. ( 2000) Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol27: 1542-1545.
22.
Goodin, D.S., Arnason, B.G., Coyle, P.K., Frohman, E.M. and Paty, D.W. ( 2003) The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology61: 1332-1338.
23.
Goodin, D.S., Frohman, E.M., Garmany Jr, G.P., Halper, J., Likosky, W.H., Lublin, F.D. et al. (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology58: 169-178.
24.
Hauser, R.A., Malek, A.R. and Rosen, R. ( 1998) Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology51: 912-913.
25.
Hemmer, B., Frohman, E., Hartung, H.P. and Stuve, O. ( 2006) Central nervous system infections - a potential complication of systemic immunotherapy. Curr Opin Neurol19: 271-276.
26.
Ishida, H., Tanabe, K., Furusawa, M., Ishizuka, T., Shimmura, H., Tokumoto, T. et al. (2002) Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity. Transplantation74: 1187-1189.
27.
Jonsson, C.A. and Carlsten, H. ( 2002) Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages. Cell Immunol216: 93-101.
28.
Karim, M.Y., Alba, P., Cuadrado, M.J., Abbs, I.C., D’Cruz, D.P., Khamashta, M.A. et al. (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 8: 876-882.
29.
Lui, S.L., Tsang, R., Wong, D., Chan, K.W., Chan, T.M., Fung, P.C. et al. (2002) Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus11: 411-418.
30.
Menge, T., Weber, M.S., Hemmer, B., Kieseier, B.C., von Budingen, H.C., Warnke, C. et al. (2008) Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs68: 2445-2468.
31.
Miljkovic, D., Samardzic, T., Drakulic, D., Stosic-Grujicic, S. and Trajkovic, V. ( 2002) Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms. Cytokine19: 181-186.
32.
Moses Jr, H. and Brandes, D.W. ( 2008) Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. Curr Med Res Opin24: 2679-2690.
33.
Mowzoon, N., Sussman, A. and Bradley, W.G. ( 2001) Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci185: 119-122.
34.
Noseworthy, J.H., Lucchinetti, C., Rodriguez, M. and Weinshenker, B.G. ( 2000) Multiple sclerosis. N Engl J Med343: 938-952.
35.
O’Connor, P.W., Li, D., Freedman, M.S., Bar-Or, A., Rice, G.P., Confavreux, C. et al. (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology66: 894-900.
36.
Pawate, S., Agarwal, A., Moses, H. and Sriram, S.(2009) The spectrum of Susac’s syndrome. Neurol Sci30: 59-64.
37.
Polman, C.H., Reingold, S.C., Edan, G., Filippi, M., Hartung, H.P., Kappos, L. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol58: 840-846.
38.
Schanz, S., Ulmer, A., Rassner, G. and Fierlbeck, G. ( 2002) Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol147: 174-178.
39.
Schrader, P., Mooser, G., Peter, R.U. and Puhl, W. ( 2002) [Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil]. Z Rheumatol61: 545-550.
40.
Schneider, C., Gold, R., Reiners, K. and Toyka, K.V. ( 2001) Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol46: 79-82.
41.
Schneider, C., Gold, R., Schafers, M. and Toyka, K.V. ( 2002) Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve25: 286-288.
42.
Treadaway, K., Cutter, G., Salter, A., Lynch, S., Simsarian, J., Corboy, J. et al. (2009) Factors that influence adherence with disease-modifying therapy in MS. J Neurol256: 568-576.
43.
Vermersch, P., Waucquier, N., Michelin, E., Bourteel, H., Stojkovic, T., Ferriby, D. et al. (2007) Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (CellCept) in multiple sclerosis. Eur J Neurol14: 85-89.
44.
Vukusic, S., Ducray, F. and Gignoux, L. ( 2004) Mycophenolatemofetil: an open-label study in 42 MS patients . Neurology62: 491.
45.
Waiser, J., Budde, K., Braasch, E. and Neumayer, H.H. ( 1999) Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis34: e9.
46.
Zivadinov, R., Bagnato, F., Nasuelli, D., Bastianello, S., Bratina, A., Locatelli, L. et al. (2004) Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J Neurol Sci223: 185-193.
47.
Zivadinov, R., Rudick, R.A., De Masi, R., Nasuelli, D., Ukmar, M., Pozzi-Mucelli, R.S. et al. (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology57: 1239-1247.
